Osaic Holdings
HRTX icon

Osaic Holdings’s Heron Therapeutics HRTX Stock Holding History

Osaic Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.82K Buy
5,860
+4,999
+581% +$1.89K ﹤0.01% 7362
2026
Q2 		$369 Sell
861
-3,000
-78% -$2.4K ﹤0.01% 7703
2026
Q1 		$3.09K Sell
3,861
-1,107
-22% -$1.28K ﹤0.01% 6890
2025
Q4 		$6.46K Buy
4,968
+1,077
+28% +$1.33K ﹤0.01% 6561
2025
Q3 		$5.25K Sell
3,891
-77
-2% -$122 ﹤0.01% 6718
2025
Q2 		$8.21K Buy
3,968
+3,000
+310% +$6.13K ﹤0.01% 6277
2025
Q1 		$2.13K Hold
968
– – ﹤0.01% 6567
2024
Q4 		$1.48K Sell
968
-441
-31% -$715 ﹤0.01% 6721
2024
Q3 		$2.8K Sell
1,409
-265
-16% -$633 ﹤0.01% 6473
2024
Q2 		$5.86K Sell
1,674
-15,508
-90% -$47.6K ﹤0.01% 6093
2024
Q1 		$47.6K Buy
17,182
+1,008
+6% +$2.53K ﹤0.01% 4789
2023
Q4 		$27.5K Sell
16,174
-2,984
-16% -$3.29K ﹤0.01% 5309
2023
Q3 		$19.7K Sell
19,158
-259
-1% -$369 ﹤0.01% 5564
2023
Q2 		$22.5K Sell
19,417
-1,571
-7% -$2.8K ﹤0.01% 5487
2023
Q1 		$31.7K Sell
20,988
-600
-3% -$1.5K ﹤0.01% 5281
2022
Q4 		$54.5K Buy
21,588
+1,341
+7% +$4.32K ﹤0.01% 4866
2022
Q3 		$85K Sell
20,247
-755
-4% -$2.95K ﹤0.01% 4506
2022
Q2 		$58K Buy
21,002
+847
+4% +$3.4K ﹤0.01% 4843
2022
Q1 		$115K Sell
20,155
-652
-3% -$4.77K ﹤0.01% 4492
2021
Q4 		$189K Sell
20,807
-21,684
-51% -$221K ﹤0.01% 3997
2021
Q3 		$456K Buy
42,491
+548
+1% +$6.67K ﹤0.01% 3120
2021
Q2 		$652K Buy
41,943
+10,308
+33% +$164K ﹤0.01% 2739
2021
Q1 		$513K Buy
31,635
+21,039
+199% +$375K ﹤0.01% 2839
2020
Q4 		$223K Buy
10,596
+2,101
+25% +$36.5K ﹤0.01% 3376
2020
Q3 		$126K Sell
8,495
-223
-3% -$3.48K ﹤0.01% 3624
2020
Q2 		$128K Buy
8,718
+6,750
+343% +$111K ﹤0.01% 3501
2020
Q1 		$23K Buy
+1,968
New +$37K ﹤0.01% 4536

Other funds holding HRTX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return

Osaic Holdings's HRTX Position: Q3 2026 in Review

Osaic Holdings increased its Heron Therapeutics (HRTX) stake by 581% in Q3 2026, buying an estimated $1.89K and bringing the position to 5,860 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #7362.

Osaic Holdings first reported a position in HRTX in Q1 2020 and has held it in 27 quarters since. The position peaked at $652K in Q2 2021. 112 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Osaic Holdings held 5,860 shares of Heron Therapeutics worth $1.82K as of Q3 2026.
  • Osaic Holdings bought 4,999 Heron Therapeutics shares in Q3 2026, an estimated $1.89K.
  • Heron Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q3 2026, its #7362 holding.
  • Osaic Holdings first reported a position in Heron Therapeutics in Q1 2020 and has held it in 27 quarters since.
  • Osaic Holdings's Heron Therapeutics position peaked at $652K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.